A detailed history of Klingman & Associates, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Klingman & Associates, LLC holds 2,507 shares of NVO stock, worth $219,036. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,507
Previous 2,522 0.59%
Holding current value
$219,036
Previous $359,000 16.99%
% of portfolio
0.02%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$119.07 - $145.42 $1,786 - $2,181
-15 Reduced 0.59%
2,507 $298,000
Q2 2024

Jul 30, 2024

BUY
$122.71 - $146.91 $89,578 - $107,244
730 Added 40.74%
2,522 $359,000
Q1 2024

May 01, 2024

BUY
$102.11 - $135.92 $182,981 - $243,568
1,792 New
1,792 $230,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Klingman & Associates, LLC Portfolio

Follow Klingman & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Klingman & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Klingman & Associates, LLC with notifications on news.